Literature DB >> 33927085

The Impact of Adverse Events on Functional Capacity and Quality of Life After HeartWare Ventricular Assist Device Implantation.

Marc D Samsky1, Carmelo A Milano1, Salpy Pamboukian2, Mark S Slaughter3, Emma Birks3, Steven Boyce4, Samer S Najjar5, Akinobu Itoh6, Bruce Reid7, Nahush Mokadam8, Keith D Aaronson9, Francis D Pagani9, Joseph G Rogers1.   

Abstract

Left ventricular assist devices (LVADs) improve quality of life (QoL) and functional capacity (FC) for patients with advanced heart failure. The association between adverse events (AEs) and changes in QoL and FC are unknown. Patients treated with the HeartWare ventricular assist device (HVAD) with paired 6-minute walk distance (6MWD, n = 263) and Kansas City Cardiomyopathy Questionnaires (KCCQ, n = 272) at baseline and 24 months in the ENDURANCE and ENDURANCE Supplemental Trial databases were included. Patients were stratified based upon occurrence of clinically significant AEs during the first 24 months of support and analyzed for the mean change in 6MWD and KCCQ. The impact of AE frequency on change in 6MWD and KCCQ from baseline to 24 months was evaluated. Of the AEs examined, only sepsis was associated with an improvement in 6MWD (109 m vs. 16 m, p = 0.002). Patients without improvement in 6MWD test from baseline to 24 months had significantly more AEs than those with FC improvement (p = 0.0002). Adverse events did not affect the KCCQ overall summary score. In this analysis, patients with fewer AEs had greater improvement in FC during the 24-month follow up. The frequency of AEs did not have a significant impact on QoL after LVAD implantation.
Copyright © ASAIO 2021.

Entities:  

Mesh:

Year:  2021        PMID: 33927085      PMCID: PMC8478694          DOI: 10.1097/MAT.0000000000001378

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   3.826


  12 in total

1.  Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy.

Authors:  Soon J Park; Carmelo A Milano; Antone J Tatooles; Joseph G Rogers; Robert M Adamson; D Eric Steidley; Gregory A Ewald; Kartik S Sundareswaran; David J Farrar; Mark S Slaughter
Journal:  Circ Heart Fail       Date:  2012-01-26       Impact factor: 8.790

2.  Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure.

Authors:  Joseph G Rogers; Francis D Pagani; Antone J Tatooles; Geetha Bhat; Mark S Slaughter; Emma J Birks; Steven W Boyce; Samer S Najjar; Valluvan Jeevanandam; Allen S Anderson; Igor D Gregoric; Hari Mallidi; Katrin Leadley; Keith D Aaronson; O H Frazier; Carmelo A Milano
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

3.  Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation: an outlook for permanent assisting?

Authors:  N de Jonge; H Kirkels; J R Lahpor; C Klöpping; E J Hulzebos; A B de la Rivière; E O Robles de Medina
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

4.  Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support).

Authors:  Ulrich P Jorde; Sudhir S Kushwaha; Antone J Tatooles; Yoshifumi Naka; Geetha Bhat; James W Long; Douglas A Horstmanshof; Robert L Kormos; Jeffrey J Teuteberg; Mark S Slaughter; Emma J Birks; David J Farrar; Soon J Park
Journal:  J Am Coll Cardiol       Date:  2014-03-05       Impact factor: 24.094

5.  Patient Perceptions and Familiarity With Medical Therapy for Heart Failure.

Authors:  Marc D Samsky; Li Lin; Stephen J Greene; Steven J Lippmann; Pamela N Peterson; Paul A Heidenreich; Warren K Laskey; Clyde W Yancy; Melissa A Greiner; N Chantelle Hardy; Abhishek Kavati; Siyeon Park; Robert J Mentz; Gregg C Fonarow; Emily C O'Brien
Journal:  JAMA Cardiol       Date:  2020-03-01       Impact factor: 14.676

6.  Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow.

Authors:  Mani A Daneshmand; Arun Krishnamoorthy; Marc D Samsky; G Michael Felker; John A Pura; Yuliya Lokhnygina; Adrian F Hernandez; Paul B Rosenberg; Laura J Blue; Jacob N Schroder; Joseph G Rogers; Carmelo A Milano; Chetan B Patel
Journal:  Am J Cardiol       Date:  2015-05-21       Impact factor: 2.778

7.  Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients.

Authors:  Joseph G Rogers; Keith D Aaronson; Andrew J Boyle; Stuart D Russell; Carmelo A Milano; Francis D Pagani; Brooks S Edwards; Soon Park; Ranjit John; John V Conte; David J Farrar; Mark S Slaughter
Journal:  J Am Coll Cardiol       Date:  2010-04-27       Impact factor: 24.094

8.  Quality of life and functional status in patients surviving 12 months after left ventricular assist device implantation.

Authors:  Jeremiah G Allen; Eric S Weiss; Justin M Schaffer; Nishant D Patel; Susan L Ullrich; Stuart D Russell; Ashish S Shah; John V Conte
Journal:  J Heart Lung Transplant       Date:  2009-10-17       Impact factor: 10.247

9.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

10.  HVAD: The ENDURANCE Supplemental Trial.

Authors:  Carmelo A Milano; Joseph G Rogers; Antone J Tatooles; Geetha Bhat; Mark S Slaughter; Emma J Birks; Nahush A Mokadam; Claudius Mahr; Jeffrey S Miller; David W Markham; Valluvan Jeevanandam; Nir Uriel; Keith D Aaronson; Thomas A Vassiliades; Francis D Pagani
Journal:  JACC Heart Fail       Date:  2018-07-11       Impact factor: 12.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.